Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/107.4.496aDOI Listing

Publication Analysis

Top Keywords

cd5 immunostaining
4
immunostaining lymphoid
4
lymphoid neoplasms
4
neoplasms paraffin
4
paraffin sections
4
cd5
1
lymphoid
1
neoplasms
1
paraffin
1
sections
1

Similar Publications

A 70-year-old man presented with the growth of an anterior mediastinal nodule on a follow-up computed tomography (CT) scan after undergoing lung cancer surgery. Positron emission tomography (PET)-CT performed at the time of lung cancer surgery did not recognize any accumulation, but PET-CT performed this time confirmed the accumulation of standardized uptake value( SUV) max 5.57.

View Article and Find Full Text PDF

The histopathological diagnosis of T-lymphoblastic leukemia/lymphoma, NOS (T-ALL), is based on morphology and positivity for CD3 and TdT. Early T-precursor lymphoblastic leukemia/lymphoma (ETP-ALL) and mixed-phenotype acute leukemia (MPAL), T/M, and/or B rarely occur and are usually diagnosed using flow cytometry. Using only formalin-fixed paraffin-embedded tissue raises the risk of misdiagnosis due to underestimation.

View Article and Find Full Text PDF

Monomorphic epitheliotropic T-cell lymphoma (MEITL) of gastrointestinal tract is an aggressive T-cell lymphoma that can rarely involve the brain. We present detailed descriptions of clinical and autopsy neuropathological findings of a rare case of an elderly woman who had surgery and chemotherapy for MEITL of the small intestine. Following her surgery, she progressively exhibited neurologic decline towards the end of her treatment.

View Article and Find Full Text PDF

Introduction: Adamantinoma-like Ewing sarcoma (ALES) is a rare aggressive malignancy occasionally diagnosed in the thyroid gland. ALES shows basaloid cytomorphology, expresses keratins, p63, p40, frequently CD99, and harbours the t(11;22) EWSR1::FLI1 translocation. There is debate on whether ALES resembles more sarcoma or carcinoma.

View Article and Find Full Text PDF

EZH2 and POU2F3 Can Aid in the Distinction of Thymic Carcinoma from Thymoma.

Cancers (Basel)

April 2023

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55902, USA.

Thymic carcinoma is an aggressive malignancy that can be challenging to distinguish from thymoma using histomorphology. We assessed two emerging markers for these entities, EZH2 and POU2F3, and compared them with conventional immunostains. Whole slide sections of 37 thymic carcinomas, 23 type A thymomas, 13 type B3 thymomas, and 8 micronodular thymomas with lymphoid stroma (MNTLS) were immunostained for EZH2, POU2F3, CD117, CD5, TdT, BAP1, and MTAP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!